This transcript has been edited for clarity:

Hi, I’m Diana Do, MD, with Retinal Physician. I’m here with my friend and colleague, David Eichenbaum, MD. Tell us about your exciting data you’re sharing at the American Society of Retina Specialists (ASRS) meeting.

David Eichenbaum, MD: I’m thrilled to be here, Diana. Thank you so much for the opportunity to talk about my presentation. I am talking about the rationale for the phase 3 ARCHER II study of vonaprument (formerly ANX007; Annexon Biosciences) in geographic atrophy. The takeaway points from this are: Number 1, we’ve fully enrolled this phase 3 study ARCHER II. Number 2, there's a global pathway to registration because the endpoint for this geographic atrophy study is vision preservation. There's an event analysis—15 letter loss is the event we're looking for—and we believe there's a good chance that vonaprument reduces the rate of vision loss. The third thing is [that] the inclusion criteria mirror what was included in the phase 2 study, which hopefully improves the probability of a phase 3 readout. The last thing is that vonaprument in phase 2 was well tolerated and merits greater study in a larger number of patients, which we're doing now.

[Vonaprument] is a monoclonal antibody fragment built on a backbone of ranibizumab, so we’re hopeful that safety will be strong and that efficacy, with regards to vision preservation, will allow this to be the first product that preserves vision in geographic atrophy.

Diana Do, MD: That would be so exciting! I know that's still an unmet need area, so thank you so much for sharing this exciting data. RP